GENEVA, Oct 1 (Reuters) - Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization said on Wednesday.
GENEVA, Oct 1 (Reuters) - Both GlaxoSmithKline and NewLink are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization (WHO) said on Wednesday.
By Wall Street Playbook : Last week, drug giant GlaxoSmithKline (NYSE: GSK ) was found guilty on bribery charges and has been ..... company rules. In a statement, the company said: " GSK Plc sincerely apologizes to the Chinese patients
At the ESMO Congress in Madrid, Spain, GlaxoSmithKline ( GSK -0.6% ) presented overall survival data from a ..... months versus 15.6 months in the dacarbazine group. GSK Oncology Chief Dr. Paolo Paoletti says, "We are
expected and similar to Novartis’ competing Mekinist and Tafinlar combination, which was recently acquired from GlaxoSmithKline and targets the same patient population, we are maintaining our $2.10 fair value estimate and no-moat, stable
MADRID, Sept 29 (Reuters) - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline have yielded similar results in separate clinical trials, leaving doctors with little to choose between the two regimens.
up over 20% YTD and outperforming its key rivals Pfizer (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ), Novartis (NYSE: NVS ), & Bristol-Myers Squibb (NYSE: BMY ) (Figure 1.). Merck is up 20% YTD
Thermo Fisher Scientific (NYSE: TMO ) enters into an agreement with GlaxoSmithKline (NYSE: GSK ) and Pfizer (NYSE: PFE ) to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will
announced on Sept. 25 that its chairman, Sir Phillip Hampton, will step down in 2015 to become the chairman of GlaxoSmithKline . We’re not surprised by Hampton’s impending departure, since he and the bank have long signaled that he
chairman of RBS since 2009, but he will step down at some point next year, and begin serving on the board at GlaxoSmithKline (NYSE: GSK ) on January 1. He's expected to succeed Christopher Gent as Glaxo's chairman by September 2015. RBS